English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims/Introduction  To evaluate the efficacy and safety of alpha‐glucosidase inhibitors ( AGI ) in Asian and non‐Asian type 2 diabetes patients.    Materials and Methods  Studies were identified through a literature search of  MEDLINE ,  EMBASE  and other databases until December 2016. All statistical analyses were carried out in Review Manager statistical software by computing the weighted mean difference or odds ratio and 95% confidence interval.    Results  A total of 67 studies were included.  AGI  vs placebo: compared with the placebo,  AGI  treatment led to a greater decrease in hemoglobin A1c (HbA1c), fasting plasma glucose and postprandial plasma glucose. No significant difference was observed in HbA1c change, fasting plasma glucose change, postprandial plasma glucose change or incidence of hypoglycemia between Asian and non‐Asian patients.  AGI  vs active controls: in Asian patients,  AGI  treatment showed a lower reduction in HbA1c compared with dipeptidyl peptidase‐4 inhibitors and sulfonylurea. In non‐Asian patients,  AGI  treatment showed a lower reduction in HbA1c compared with thiazolidinedione. No significant difference was observed in HbA1c change and bodyweight change when comparing  AGI  with other oral hypoglycemic agents between Asian and non‐Asian patients.    Conclusions  The effects of  AGI  treatment on glycemic control and bodyweight reduction were superior to the placebo without an increased incidence of hypoglycemia, but with an increased incidence of gastrointestinal discomforts. The hypoglycemic effects of  AGI  were comparable between Asian and non‐Asian patients.

Meta‐analysis and critical review on the efficacy and safety of alpha‐glucosidase inhibitors in Asian and non‐Asian populations